Shares in FTSE 250’s Oxford Nanopore Technologies surged on Friday as it set out positive guidance for the full-year.
The Oxford-based DNA and RNA sequencing specialist said it expects 2025 constant-currency revenue growth to be at the top end of its 20% to 23% target range, with all other financial metrics tracking in line with expectations.
Its shares have climbed by over 6% to 143p as of 2:45pm today and it holds a market cap of £1.38 billion.
The company is also still looking for a new CEO, with a succession process underway as Gordon Sanghera, who has spearheaded the MedTech since its inception in 2005, will leave at the end of 2025.
Rightmove shares tumble as FTSE 100 firm lowers profit guidance
He has guided the company through milestones including a 2021 IPO, an inclusion in the FTSE 250 index in 2024 and a market cap which peaked at over £2bn.
He initially set up the University of Oxford spinout after spending 16 years as an R&D director at US-based healthcare giant Abbott.
The company’s technology is used in more than 125 countries to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer.
Its revenue in 2024 hit £183.2 million, rising by 8%.
£2m Leeds incubator to aid region’s booming HealthTech sector